Cancer therapy takes on autoimmune thyroid disease
NCT ID NCT07261345
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tests a single infusion of genetically modified immune cells (CAR-T cells) in 4 people with refractory Graves' disease, a thyroid condition that doesn't respond well to standard medication. The cells target two proteins (CD19 and BCMA) to reset the immune system. The goal is to see if this approach can safely lead to remission, meaning normal thyroid function without needing daily drugs.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
allogenic anti-CD19/BCMA CAR-T cells (RD06-05)
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-control Graves' disease, potentially allowing them to stop long-term medication.
What could go wrong
This is a very early, small trial with only 4 participants. CAR-T therapy can cause serious side effects, and it's unknown if it will work for Graves' disease or provide lasting benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRAVES DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••